Öz
Candida auris ilk olarak 2009 yılında Japonya’da izole edilmiş ve o zamandan bu yana dünya çapında 25’ten fazla ülkede rapor edilmiştir. Yüksek ölüm oranlarına sahip invazif enfeksiyonlara neden olabilen bu türün geleneksel biyokimyasal yöntemler ile tanımlanması zordur. C. auris deride kolonize olarak hastanede yatan hastalar arasında bulaşabilir. Bu tür içinde flukonazole ve amfoterisin B’ye direnç yaygındır ve bazı ülkelerde tedavide tercih edilen ekinokandinlere karşı da direncin geliştiği görülmektedir. Yapılan çalışmalarda, antifungallere karşı oluşan direncin intirensek değil kazanılmış olduğu gösterilmiş, ekinokandin ve azollere karşı birincil direnç mekanizmaları belirlenmiştir. Çoğul ilaca dirençli olmaları, hatta pan-rezistan suşların ortaya çıkması, klinik mikrobiyoloji laboratuvarlarında geleneksel yöntemlerle yanlış tanımlanmaları ve hastane ortamında uzun süre kalabilmeleri nedeniyle bu türün kontrol altına alınması zordur. Enfeksiyon kontrol önlemleri ile enfeksiyonların önlenebilmesi için doğru tanı konulabilmesine olanak sağlayan gelişmiş laboratuvar yöntemlerine ihtiyaç vardır. Ayrıca tedavide başarının sağlanması için yeni antifungal ilaçların araştırılması ve uygulamaya dahil edilmesi gerekmektedir. Bu kısa derlemede, C. auris’in epidemiyolojisi, oluşturduğu enfeksiyonlar, mikrobiyolojik özellikleri ve laboratuvar tanısı hakkında güncel bilgilere değinilmiştir.
Anahtar Kelimeler: Candida auris, tanı, antifungal ilaç direnci, Candida
Kaynakça
Alangaden GJ. Nosocomial fungal infections: epidemiology, infection control, and prevention, Infect Dis Clin Nort Am. 2011;25:201-25.
Colombo AL, Guimarães T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, Nouér SA, Nucci M. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med. 2014; 40:1489-98.
Giacomazzi J, Baethgen L, Carneiro LC, Millington MA, Denning DW, Colombo AL, Pasqualotto AC; Association With The LIFE Program. The burden of serious human fungal infections in Brazil. Mycoses. 2016;59:145-50.
de Cássia Orlandi Sardi J, Silva DR, Soares Mendes-Giannini MJ, Rosalen PL. Candida auris: Epidemiology, risk factors, virulence, resistance, and therapeutic options. Microbial Pathog. 2018;125:116-21.
Daniel HM, Lachance MA, Kurtzman CP. On the reclassification of species assigned to Candida and other anamorphic ascomycetous yeast genera based onphylogenetic circumscription. Antonie Van Leeuwenhoek. 2014;106:67-84
Brandt ME, Lockhart SR. Recent taxonomic developments with Candida and other opportunistic yeasts. Curr Fungal Infect Rep. 2012;6:170-7.
Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata. Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol. 2012;36:288-305.
Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS pathog. 2020;16:e1008921.
Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:41-4.
Iguchi S, Mizushima R, Kamada K, Itakura Y, Yoshida A, Uzawa Y, Arai Y, Umeyama T, Miyazaki Y, Sekizuka T, Kuroda M, Makimura K, Kikuchi K. 2051. Detection of Candida auris Among Previously Unidentified Yeasts Isolated from Ear Discharge Specimens in Japan. In Open Forum Infect Dis. 2018;5(Suppl 1):598-9.
Iguchi S, Mizushima R, Kamada K, Itakura Y, Yoshida A, Uzawa Y, Arai Y, Takaoka M, Sato S, Goto A, Karasawa T, Tsuruoka N, Totsuka D, Ono E, Nonaka M, Makimura K, Kikuchi K. The second Candida auris isolate from aural discharge in Japan. Jpn J Infect Dis. 2018;71:174-5.
Sarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155-65.
Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, Hewitt C, Simner PJ, Carroll KC, Hayden RT, Zhang SX. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories? J Clin Microbiol. 2017;55:638-40.
CDC. Centers for Disease control and Prevention. Recommendations for identification of Candida auris. Last Accessed Date: 12 November 2018. Available from: https://www.cdc.gov/fungal/candida-auris/ recommendations.html
Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, Jang HC. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49:3139-42.
Kurt AF, Kuskucu MA, Balkan II, Baris A, Yazgan Z, Serife Oz A, Tosun AI, Mete B, Tabak F, Aygun G. Candida auris Fungemia and a local spread taken under control with infection control measures: First report from Turkey. Indian J Med Microbiol. 2021;39:228-30.
Bölükbaşı Y, Erköse Genç G, Orhun G, Kuşkucu MA, Çağatay A, Önel M, Öngen B, Ağaçfidan A, Esen F, Erturan Z. First Case of COVID-19 Positive Candida auris Fungemia in Turkey. Mikrobiyol Bul. 2021;55:648-55.
Kömeç S, Karabıçak N, Ceylan AN, Gülmez A, Özalp O. Three Candida auris Case Reports from Istanbul, Turkey. Mikrobiyol Bul. 2021;55:452-60.
Lockhart SR, Berkow EL, Chow N, Welsh RM. Candida auris for the clinical microbiology laboratory: not your grandfather’s Candida species. Clin Microbiol Newsl. 2017;39:99-103.
Rhodes J, Fisher MC. Global epidemiology of emerging Candida auris. Curr Opin Microbiol. 2019;52:84-9.
CDC. Clinical Alert to U.S.. Healthcare facilities, June 2016, fungal diseases, 2017. Last Accessed Date: December 9, 2017. Available from: https://www.cdc.gov/fungal/diseases/ candidiasis/candida-auris-alert.html
Azar MM, Turbett SE, Fishman JA, Pierce VM. Donor-derived transmission of Candida auris during lung transplantation. Clin Infect Dis. 2017;65:1040-2.
Snyder GM, Wright SB. The epidemiology and prevention of Candida auris. Curr Infec Dis Rep. 2019;21:19.
Ong CW, Chen SC, Clark JE, Halliday CL, Kidd SE, Marriott DJ, Marshall CL, Morris AJ, Morrissey CO, Roy R, Slavin MA, Stewardson AJ, Worth LJ, Heath CH; Australian and New Zealand Mycoses Interest Group (ANZMIG); and the Healthcare Infection Control Special Interest Group (HICSIG); both of the Australasian Society for Infectious Diseases (ASID). Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases. Intern Med J. 2019;49:1229-43.
Sikora A, Zahra F. Candida auris. [Updated 2021 Sep 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Last Accessed Date: Jan 2021. Available from: https://www.ncbi.nlm.nih.gov /books/NBK563297/
Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A; Candida auris Incident Management Team, Manuel R, Brown CS. Candida auris: a review of the literature. Clin Microbiol Rev. 2018;31:e00029-17.
Bradley SF. Candida auris Infection. JAMA. 2019;322:1526.
Lone SA, Ahmad A. Candida auris-the growing menace to global health. Mycoses. 2019;62:620-37
Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6:69.
Jung J, Kim MJ, Kim JY, Lee JY, Kwak SH, Hong MJ, Chong YP, Lee SO, Choi SH, Kim YS, Woo JH, Kang WS, Chung JW, Kim MN, Kim SH. Candida auris colonization or infection of the ear: A single-center study in South Korea from 2016 to 2018. Med Mycol. 2020;58:124-7.
Ruiz Gaitán AC, Moret A, López Hontangas JL, Molina JM, Aleixandre López AI, Cabezas AH, Mollar Maseres J, Arcas RC, Gómez Ruiz MD, Chiveli MÁ, Cantón E, Pemán J. Nosocomial fungemia by Candida auris: first four reported cases in continental Europe. Rev Iberoam Micol. 2017;34:23-7.
Dahiya S, Chhillar AK, Sharma N, Choudhary P, Punia A, Balhara M, Kaushik K, Parmar VS. Candida auris and Nosocomial Infection. Curr Drug Targets. 2020;21:365-73.
Uppuluri P. Candida auris Biofilm Colonization on Skin Niche Conditions. mSphere. 2020;5:e00972-19.
Biswal M, Rudramurthy SM, Jain N, Shamanth AS, Sharma D, Jain K, Yaddanapudi LN, Chakrabarti A. Controlling a possible outbreak of Candida auris infection: lessons learnt from multiple interventions. J Hosp Infect. 2017;97:363-70.
Horton MV, Johnson CJ, Kernien JF, Patel TD, Lam BC, Cheong JZA, Meudt JJ, Shanmuganayagam D, Kalan LR, Nett JE. Candida auris Forms High-Burden Biofilms in Skin Niche Conditions and on Porcine Skin. mSphere. 2020;5:e00910.
Spivak ES, Hanson KE. Candida auris: an Emerging Fungal Pathogen. J Clin Microbiol. 2018;56:e01588-17.
Keighley C, Garnham K, Harch SAJ, Robertson M, Chaw K, Teng JC, Chen SC. Candida auris: Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology Laboratory. Curr Fungal Infect Rep. 2021:1-11.
Kumar J, Eilertson B, Cadnum JL, Whitlow CS, Jencson AL, Safdar N, Krein SL, Tanner WD, Mayer J, Samore MH, Donskey CJ. Environmental Contamination with Candida Species in Multiple Hospitals Including a Tertiary Care Hospital with a Candida auris Outbreak. Pathog Immun. 2019;4:260-70.
Cortegiani A, Misseri G, Giarratano A, Bassetti M, Eyre D. The global challenge of Candida auris in the intensive care unit. Crit Care. 2019;23:150.
Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134-40.
Bidaud AL, Chowdhary A, Dannaoui E. Candida auris: an emerging drug resistant yeast - A mini-review. J Mycol Med. 2018;28:568-73.
Mahmoudi S, Agha Kuchak Afshari S, Aghaei Gharehbolagh S, Mirhendi H, Makimura K. Methods for identification of Candida auris, the yeast of global public health concern: A review. J Mycol Med. 2019;29:174-9.
Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, Meis JF, Chowdhary A. Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. J Clin Microbiol. 2015;53:1823-30.
Gülmez D. Candida auris: The Fungal Pathogen That Managed to Spread Around the World in a Decade. FLORA. 2019;24:263-71.
Tsay S, Kallen A, Jackson BR, Chiller TM, Vallabhaneni S. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast. Clin Infect Dis. 2018;66:306-11.
Lu PL, Liu WL, Lo HJ, Wang FD, Ko WC, Hsueh PR, Ho MW, Liu CE, Chen YH, Chen YC, Chuang YC, Chang SC. Are we ready for the global emergence of multidrug-resistant Candida auris in Taiwan? J Formos Med. 2018;117:462-70.
Saris K, Meis JF, Voss A. Candida auris. Curr Opin Infect Dis. 2018;31:334-40.
Iguchi S, Itakura Y, Yoshida A, Kamada K, Mizushima R, Arai Y, Uzawa Y, Kikuchi K. Candida auris: a pathogen difficult to identify, treat, and eradicate and its characteristics in Japanese strains. J Infect Chemother. 2019;25:743-9.
Ruiz-Gaitán AC, Fernández-Pereira J, Valentin E, Tormo-Mas MA, Eraso E, Pemán J, de Groot PWJ. Molecular identification of Candida auris by PCR amplification of species-specific GPI protein-encoding genes. Int J Med Microbiol. 2018;308:812-8.
Asadzadeh M, Ahmad S, Al-Sweih N, Khan Z. Rapid and Accurate Identification of Candida albicans and Candida dubliniensis by Real-Time PCR and Melting Curve Analysis. Med Princ Pract. 2018;27:543-8.
Leach L, Zhu Y, Chaturvedi S. Development and Validation of a Real-Time PCR Assay for Rapid Detection of Candida auris from Surveillance Samples. J Clin Microbiol. 2018;56:e01223-17.
Yamamoto M, Alshahni MM, Tamura T, Satoh K, Iguchi S, Kikuchi K, Mimaki M, Makimura K. Rapid Detection of Candida auris Based on Loop-Mediated Isothermal Amplification (LAMP). J Clin Microbiol. 2018;56:e00591-18.
Hou X, Lee A, Jiménez-Ortigosa C, Kordalewska M, Perlin DS, Zhao Y. Rapid detection of ERG11-associated azole resistance and FKS-associated echinocandin resistance in Candida auris. Antimicrob Agents Chemother. 2019;63:e01811-8.
Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, Dinesh KR, Karim S, Singh SK, Hagen F, Meis JF. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33:919-26.
Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017;61:e00485-17.
Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, Maor Y, Tarabia J, Schechner V, Adler A, Finn T. Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23:195-203.
Ruiz-Gaitán AC, Cantón E, Fernández-Rivero ME, Ramírez P, Pemán J. Outbreak of Candida auris in Spain: a comparison of antifungal activity by three methods with published data. Int J Antimicrob Agents. 2019;53:541-6.
Kordalewska M, Perlin DS. Molecular diagnostics in the times of surveillance for Candida auris. J Fungi (Basel). 2019;5:77.
Rudramurthy SM, Chakrabarti A, Paul RA, Sood P, Kaur H, Capoor MR, Kindo AJ, Marak RSK, Arora A, Sardana R, Das S, Chhina D, Patel A, Xess I, Tarai B, Singh P, Ghosh A. Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother. 2017;72:1794-801.
Vatanshenassan M, Boekhout T, Meis JF, Berman J, Chowdhary A, Ben-Ami R, Sparbier K, Kostrzewa M. Candida auris identification and rapid antifungal susceptibility testing against echinocandins by MALDI-TOF MS. Front Cell Infect Microbiol. 2019;9:20.
Lockhart SR. Candida auris and multidrug resistance: Defining the new normal. Fungal Genet Biol. 2019;131:103243.
Jallow S, Govender NP. Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor. J Fungi (Basel). 2021;7:163.
Gamal A, Chu S, McCormick TS, Borroto-Esoda K, Angulo D, Ghannoum MA. Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata. Front Cell Infect Microbiol. 2021;11:642358.
Ghannoum M, Arendrup MC, Chaturvedi VP, Lockhart SR, McCormick TS, Chaturvedi S, Berkow EL, Juneja D, Tarai B, Azie N, Angulo D, Walsh TJ. Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections. Antibiotics (Basel). 2020;9:539.
Ham YY, Lewis JS, Thompson GR. Rezafungin: a novel antifungal for the treatment of invasive candidiasis. Future Microbiol. 2021;16:27-36.
Arendrup MC, Chowdhary A, Jørgensen KM, Meletiadis J. Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs. Antimicrob Agents Chemother. 2020;64:e00656-20.
Wiederhold NP, Patterson HP, Tran BH, Yates CM, Schotzinger RJ, Garvey EP. Fungal-specific Cyp51 inhibi-tor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, inclu-ding Coccidioides species, Aspergillus species and Rhizopus arrhizus. J Antimicrob Chemother. 2018;73:404-8.
